Compare ONDS & TFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ONDS | TFX |
|---|---|---|
| Founded | 2014 | 1943 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Medical/Dental Instruments |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8B | 4.6B |
| IPO Year | 2015 | 1994 |
| Metric | ONDS | TFX |
|---|---|---|
| Price | $10.42 | $122.48 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 10 |
| Target Price | $19.00 | ★ $140.22 |
| AVG Volume (30 Days) | ★ 68.3M | 975.6K |
| Earning Date | 04-14-2026 | 05-27-2026 |
| Dividend Yield | N/A | ★ 1.11% |
| EPS Growth | ★ 30.68 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $7,192,694.00 | ★ $1,992,713,000.00 |
| Revenue This Year | $582.00 | $9.54 |
| Revenue Next Year | $267.80 | $10.52 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.57 | $100.18 |
| 52 Week High | $15.28 | $143.32 |
| Indicator | ONDS | TFX |
|---|---|---|
| Relative Strength Index (RSI) | 49.67 | 68.41 |
| Support Level | $5.26 | $117.58 |
| Resistance Level | $11.64 | $126.38 |
| Average True Range (ATR) | 1.00 | 4.83 |
| MACD | 0.05 | 1.92 |
| Stochastic Oscillator | 45.33 | 94.96 |
Ondas Holdings Inc designs, develops, manufactures, sells, and supports FullMAX Software Defined Radio (SDR) technology in the United States, Israel, and India. The company operates in two business segments namely Ondas Networks and Ondas Autonomous Systems. The company generates maximum revenue from Ondas Autonomous Systems through the sales of the Optimus system and separately priced support, maintenance, and ancillary services related to the sale of the Optimus system.
Teleflex is a Wayne, Pennsylvania-based manufacturer of hospital supplies and medical devices primarily in the bloodstream/vascular and surgical areas. The firm reports results across seven segments: vascular access (24% of 2024 sales), interventional (19%), anesthesia (13%), surgical (15%), interventional urology (11%), original-equipment manufacturing (11%), and other (7%). Geographic exposure for the business is primarily in the US, which accounts for 60% of revenue, with international markets making up the remainder.